Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro.
Chen J, Schmitt A, Chen B, Rojewski M, Ringhoffer M, von Harsdorf S, Greiner J, Guillaume P, Döhner H, Bunjes D, Schmitt M.
Chen J, et al. Among authors: schmitt m, schmitt a.
Cancer Immunol Immunother. 2007 Jun;56(6):849-61. doi: 10.1007/s00262-006-0232-9. Epub 2006 Sep 29.
Cancer Immunol Immunother. 2007.
PMID: 17009043
Free PMC article.